Erosive-ulcer diseases of the gastroduodenal zone among servicemen: clinical and pharmacoeconomic aspects

Keywords: erosive gastritis, gastric ulcer, duodenal ulcer, pharmacoeconomic indicators, economic benefit

Abstract

Introduction. The article analyzes the distribution and structure of erosive and ulcerative diseases of the gastroduodenal zone in military personnel who were treated at the National Military Medical Clinical Center "Main Military Clinical Hospital" (NMMCC "MMCH"). Comparisons of pharmacoeconomic indicators of individual regimens for the treatment of such diseases and the potential economic benefits from their use were made.

Purpose: to analyze the clinical and pharmacoeconomic indicators of the diagnosis and treatment of erosive and ulcerative diseases of the gastroduodenal zone in military personnel and to determine the potential economic benefit when using various treatment regimens for such diseases.

Materials and methods. An analysis of the reporting documents of the NMMCC "MMCH" regarding 3904 servicemen who were treated with diagnoses of gastric ulcer, duodenal ulcer, gastritis and duodenitis was carried out. The pharmacoeconomic parameters of the standard and bismuth-containing regimens were compared and the potential economic benefit for the NMMCC "MMCH" was calculated.

Results. It was found that over a 5-year statistical series, 184 cases of gastric ulcer, 1023 cases of duodenal ulcer and 2697 cases of gastritis and duodenitis were registered at the NMMCC "MMCH". Treatment regimens with the inclusion of rabeprazole and colloidal bismuth of a domestic manufacturer showed the best cost-effectiveness and cost-utility. Potential economic benefit for NMMCC "MMCH" when using schemes with rabeprazole and bismuth in a 5-year perspective is about 473,000 UAH.

Conclusions. The use of domestic rabeprazole and colloidal bismuth in the treatment regimens of H.pylori-associated erosive and ulcerative diseases of the stomach and duodenum in military personnel demonstrates the best therapeutic and pharmacoeconomic indicators and is economically beneficial for use in the NMMCC "MMCH".

Author Biographies

G. V. Osyodlo, Ukrainian Military Medical Academy

Col MS, MD, Professor, Head of the Department of Military Therapy of the Ukrainian Military Medical Academy

O. V. Tsyts, National Military Medical Clinical Center "MMCH"

Col MS, PhD, Deputy Head for the Medical Unit of the National Military Medical Clinical Center "MMCH"

S. M. Prokopchuk, National Military Medical Clinical Center "MMCH"

Col MS, PhD, Head of the Gastroenterology Clinic of the National Military Medical Clinical Center "MMCH"

Y. Y. Kotyk, Ukrainian Military Medical Academy

Captain MS, graduate student of the Scientific and Organizational Department of the Ukrainian Military Medical Academy

V. V. Osyodlo, Ukrainian Military Medical Academy

Candidate of Pharmaceutical Sciences, Senior Lecturer of Department of Military Pharmacy, Ukrainian Military Medical Academy

References

AlRuthia, Y., Almadi, M. A., Alqahtani, S., Alrasheed, H., Al-Owairdhi, M., & Alsohaibani, F. (2021). The cost-effectiveness of sequential versus standard triple therapy for Helicobacter pylori eradication in Saudi Arabia. Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association, 27(4), 217–222. https://doi.org/10.4103/sjg.sjg_536_20

Iwasaki, H., Shimura, T., Yamada, T., Nishigaki, R., Okuda, Y., Fukusada, S., … Kataoka, H. (2021). Novel and Simple Criteria for Predicting Mortality of Peptic Ulcer Disease. Internal Medicine, 60(15), 2349–2356. https://doi.org/10.2169/internalmedicine.6945-20

Kajihara, Y., Shimoyama, T., & Mizuki, I. (2017). Analysis of the cost-effectiveness of using vonoprazan-amoxicillin-clarithromycin triple therapy for first-line Helicobacter pylori eradication. Scandinavian journal of gastroenterology, 52(2), 238–241. https://doi.org/10.1080/00365521.2016.1250157

Kavitt, R. T., Lipowska, A. M., Anyane-Yeboa, A., & Gralnek, I. M. (2019). Diagnosis and Treatment of Peptic Ulcer Disease. The American Journal of Medicine, 132(4), 447–456. https://doi.org/10.1016/j.amjmed.2018.12.009

Kubra Hussaini, S. Z., Humaira Hussaini, S. Z., Yasmeen, R., Unnisa, B., Syed, A., Khan, M. N., & Hassan, S. I. (2018). Comparison of efficacy and pharmacoeconomics of two Helicobacter pylori eradication regimens in peptic ulcer disease. Perspectives in clinical research, 9(1), 4–8. https://doi.org/10.4103/picr.PICR_99_16

Lanas, A, Chan F. (2017). Peptic ulcer disease. Lancet. 390 (10094): 613-624. https://doi.org/10.1016/S0140-6736(16)32404-7.

Malik, T. F., Gnanapandithan, K., & Singh, K. (2021). Peptic Ulcer Disease. In StatPearls. StatPearls Publishing.

Malmi, H., Kautiainen, H., Virta, L. J., & Färkkilä, M. A. (2016). Increased short- and long-term mortality in 8146 hospitalised peptic ulcer patients. Alimentary Pharmacology & Therapeutics, 44(3), 234–245. https://doi.org/10.1111/apt.13682

Pourfarzi, F., Zahirian Moghadam, T., Zandian, H., Malekzadeh, R., & Yazdanbod, A. (2021). Cost-effectiveness analysis of two routine therapeutic methods for Helicobacter pylori eradication: a Persian cohort-based study. Gastroenterology and hepatology from bed to bench, 14(3), 250–259.

Savoldi, A., Carrara, E., Graham, D. Y., Conti, M., & Tacconelli, E. (2018). Prevalence of antibiotic resistance in Helicobacter pylori: a systematic review and meta-analysis in World Health Organization regions. Gastroenterology, 155(5), 1372-1382.

Siddique, O., & Moss, S. F. (2018). Editorial: Helicobacter pylori resistance and sequential therapy. Alimentary Pharmacology & Therapeutics, 48(1), 95–96. https://doi.org/10.1111/apt.14643

Georgopoulos, S., Papastergiou, V. (2021). An update on current and advancing pharmacotherapy options for the treatment of H. pylori infection. Expert Opinion on Pharmacotherapy. 22(6), 729-741. https:// doi.org/10.1080/14656566.2020.1845649

Kotyk, Yurii (2021). Analysis of the effectiveness of gastric ulcer eradicational therapy in servicemen. Norwegian Journal of Development of the International Science, 67. P.34-37. https://doi.org/10.24412/3453-9875-2021-67-34-37

Gradov, A.P., Grinevich, V.B. (2000). Konceptualnye osnovy opredeleniya mediko-ekonomicheskoj effektivnosti lechebnyh processov. Gedeon Rihter v SNG, 3. 5-9. (In Russian).

Perepelychna, Ya. (2021). Osnovni pokaznyky invalidnosti ta diialnosti medyko-sotsialnykh ekspert-nykh komisii Ukrainy za 2020 rik: analityko-informatsiinyi dovidnyk. Dnipro: Aktsent PP. (In Ukrainian).

Osyodlo, G., Kotyk, Y., Kalashnikov, M., Osyodlo, V. (2021). Rozpovsyudzhenist, klinichnij perebig ta likuvannya hronichnogo gastritu na suchasnomu etapi. Gastroenterologiya, 55(2), 74–80. https://doi.org/10.22141/2308-2097.55.2.2021.233627 (In Ukrainian).

Osyodlo, G., Kotyk, Y. (2021). Erozivni urazhennya gastroduodenalnoyi zoni u vijskovosluzhbovciv: klinichni ta farmakoekonomichni aspekt. Simejna medicina. 5-6. (In Ukrainian).

Palii, I.H., Zaika, S.V., Kondratiuk, N.M. (2017). Shlyahi pokrashhennya efektivnosti eradikaciyi Helicobacter pylori: misce pantoprazolu. Zdorovia Ukrainy. 3(45). .47-49 (In Ukrainian).

Skrypnyk, I., Neporada K., Hopko, O. (2017). Rol stresu v patogenezi peptichnoyi virazki gastroduodenalnoyi zoni. Visnyk problem biologii ta medycyny.4. 70-73 (In Ukrainian).

Farm Eksplorer kompaniyi Proksima Reserch Ukrayina. URL: http://pharmxplorer.com.ua.

Jakovljeva, L. V. (2009). Farmakoekonomika: navch. posibnik (dlya studentiv). Vinnycia: Nova knyga. (In Ukrainian).

Published
2022-03-12
How to Cite
Osyodlo, G. V., Tsyts, O. V., Prokopchuk, S. M., Kotyk, Y. Y., & Osyodlo, V. V. (2022). Erosive-ulcer diseases of the gastroduodenal zone among servicemen: clinical and pharmacoeconomic aspects. Ukrainian Journal of Military Medicine, 3(1), 51-59. https://doi.org/10.46847/ujmm.2022.1(3)-051

Most read articles by the same author(s)